Alkem Laboratories Q2 results: net profit falls 11.7% to Rs 675.3 crore
Alkem Laboratories said in its filing that consolidated net profit attributable to owners for the September 2026 quarter was Rs 675.3 crore, down 11.7% year on year, on revenue of Rs 4,552.0 crore.
Key points
- Alkem Laboratories filed unaudited consolidated Q2 FY27 results with the National Stock Exchange on 12 November 2026.
- Net profit attributable to owners was Rs 675.3 crore, down 11.7% year on year, while revenue from operations rose 13.8% to Rs 4,552.0 crore.
- The filing shows total tax expense of Rs 331.9 crore, against Rs 116.2 crore in the same quarter a year earlier.
Alkem Laboratories Limited reported consolidated net profit attributable to its owners of Rs 675.3 crore for the quarter ended 30 September 2026, down 11.7% from a year earlier, in a filing with the National Stock Exchange on 12 November 2026. Revenue from operations rose 13.8% year on year to Rs 4,552.0 crore.
What Happened
The company said its Board approved the unaudited standalone and consolidated results for the second quarter (Q2 FY27) and the six months ended 30 September 2026 at a meeting held on 12 November 2026. The figures below are consolidated, which include its subsidiaries.
Revenue from operations was Rs 4,552.0 crore, against Rs 4,001.0 crore in the September 2025 quarter (up 13.8%) and Rs 3,740.2 crore in the June 2026 quarter (up 21.7%).
Net profit attributable to the owners of the company was Rs 675.3 crore, against Rs 765.1 crore a year earlier (down 11.7%) and Rs 520.0 crore in the previous quarter (up 29.9%). Basic and diluted earnings per share were Rs 56.48, against Rs 63.99 a year earlier and Rs 43.49 in the previous quarter.
Profit before tax, after an exceptional item, was Rs 999.7 crore. The exceptional item was a gain of Rs 35.0 crore, which the filing says is a recovery against an investment that was impaired in the quarter and year ended 31 March 2026. Total tax expense was Rs 331.9 crore, against Rs 116.2 crore a year earlier. The filing says the company opted for the new tax regime from financial year 2026-27, and that tax expense in the current period is recognised at the rates applicable under that regime.
For the six months, revenue from operations was Rs 8,292.1 crore, against Rs 7,372.1 crore a year earlier. Net profit attributable to owners was Rs 1,195.3 crore, against Rs 1,429.3 crore.
The auditors, Deloitte Haskins & Sells LLP, issued an unmodified review report on the results.
What It Means
Revenue grew in the quarter against both comparison periods, while profit attributable to owners fell against the year-earlier quarter. The filing's own table shows a sharply higher tax charge than a year earlier, alongside higher finance costs and employee costs; it does not give a single reason for the lower profit.
These are the company's own unaudited figures, reviewed but not audited by its auditors. The full results, including the standalone statement, are available under the company's announcements on the National Stock Exchange's website.
Oquilia Data: Alkem Laboratories Ltd. (NSE: ALKEM)
| Close, 11 Nov 2026 | Rs 5,448.00 (+0.92% on the day) |
|---|---|
| Return 1M / 3M / 6M / YTD / 1Y | +3.20% / −1.44% / −2.71% / −1.06% / −4.36% |
| Against Nifty 50, 1M / 3M / YTD | −8.94 / −4.64 / +2.28 points |
| 52-week closing high / low | Rs 5,890.00 (11 Feb 2026) / Rs 4,947.00 (23 Oct 2026) |
| Turnover, 20-session average | Rs 50.48 cr; 52.6% delivered; latest volume 1.5x |
Closes adjusted for splits and bonuses; returns exclude dividends. Facts from NSE's files, not investment advice.
Full record: Alkem Laboratories share price on Oquilia
Source: Company filing on NSE
Sources & Citations
- Company filing on NSE — National Stock Exchange of India